



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO. ATTORNEY DOCKET NO. FILING DATE FIRST NAMED INVENTOR CONFIRMATION NO. **BB-1163 US DIV** 10/051,902 Stephen M. Allen -3372 01/17/2002 **EXAMINER** 23906 7590 08/26/2004 E I DU PONT DE NEMOURS AND COMPANY ROBINSON, HOPE A LEGAL PATENT RECORDS CENTER **ART UNIT** PAPER NUMBER **BARLEY MILL PLAZA 25/1128** 4417 LANCASTER PIKE 1653 WILMINGTON, DE 19805

DATE MAILED: 08/26/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)
	10/051,902	ALLEN ET AL.
Office Action Summary	Examiner	Art Unit
	Hope A. Robinson	1653
The MAILING DATE of this communication Period for Reply	appears on the cover sheet wit	th the correspondence address
A SHORTENED STATUTORY PERIOD FOR RETHE MAILING DATE OF THIS COMMUNICATION - Extensions of time may be available under the provisions of 37 CFI after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, and a lift NO period for reply is specified above, the maximum statutory period for reply within the set or extended period for reply will, by standard patent term adjustment. See 37 CFR 1.704(b).	N. R 1.136(a). In no event, however, may a real. a reply within the statutory minimum of thirty eriod will apply and will expire SIX (6) MONT tatute, cause the application to become ABA	eply be timely filed (30) days will be considered timely. THS from the mailing date of this communication. ANDONED (35 U.S.C. § 133).
Status	%.*	
1) Responsive to communication(s) filed on 0	1 June 2004.	
2a) ☐ This action is FINAL . 2b) ☑ ²	This action is non-final.	
3) Since this application is in condition for allocation closed in accordance with the practice und		
Disposition of Claims		
4) Claim(s) 16-31 is/are pending in the application 4a) Of the above claim(s) 24-31 is/are with 5) Claim(s) is/are allowed. 6) Claim(s) 16-23 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction are	drawn from consideration.	
Application Papers	•	
9) The specification is objected to by the Exam	niner.	
10)⊠ The drawing(s) filed on <u>20 May 2002</u> is/are: a)⊠ accepted or b		
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).		
Replacement drawing sheet(s) including the country and the country and the country are the country and the country are the country and the country are the cou		
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for fore a) All b) Some * c) None of: 1. Certified copies of the priority document	nents have been received. The nents have been received in Appriority documents have been reau (PCT Rule 17.2(a)).	oplication No received in this National Stage
Attachment(s)		
 Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) 	· —	ummary (PTO-413))/Mail Date
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB Paper No(s)/Mail Date 2003 O1 (-7		formal Patent Application (PTO-152)

Application/Control Number: 10/051,902 Page 1

Art Unit: 1653

DETAILED ACTION

Application Status

- 1. Applicant's election without traverse of Group I (claims 16-24) on June 1, 2004 is acknowledged. Upon due reconsideration, applicant was notified that a further restriction was needed to remove claim 24 from Group I. A telephonic election was made without traverse on August 17, 2004 by applicant's representative Ms. Dawn Clark, thus Group I remains elected comprising claims 16-23.
- 2. The Amendments filed on June 1, 2004 have been received and entered in part. It is noted that applicant instructed the office to correct the sequence listing in the specification, however, applicant needs to submit a new sequence listing and computer readable form pursuant to 37 CFR 1.825(a) and the appropriate statement indicating that the two are the same.

Change of Inventorship

3. In view of the Petition filed on June 1, 2004, the inventorship in this application has been changed by the deletion of inventor Scott V. Tingey. Issuance of a corrected filing receipt reflecting the correction of inventorship will occur under a separate cover.

Claim Disposition

Art Unit: 1653

4. Claims 1-15 have been canceled. Claims 16-19 have been amended. Claims 16-31 are pending. Claims 16-23 are under examination.

Drawing

5. The Drawings filed on May 20, 2002 are accepted by the Examiner.

Information Disclosure Statement

6. The Information Disclosure Statement filed on January 17, 2002 has been received and entered. The references cited on the PTO-1449 Form have been considered by the examiner and a copy is attached to the instant Office action.

Specification

- 7. The specification is objected to because of the following informalities:
- (a) The specification is objected to because trademarks are disclosed throughout the instant specification and not all of them are capitalized or accompanied by the generic terminology. The use of the trademarks such as Tris-HCL, for example, have been noted in this application (see page 27). It should be capitalized wherever it appears and be accompanied by the generic terminology. Although the use of trademarks is permissible in patent applications, the proprietary nature of the marks should be respected and every effort made to prevent their use in any manner, which might adversely affect their validity as trademarks.

Art Unit: 1653

- (b) The specification is also objected to because the Brief Description of the Drawings on page 2, only describes Figure 1 and does not mention parts A-E and only describes Figure 2 and parts A-D are not mentioned in the description.
- (c) The title of the Invention is not descriptive. A new title is required that is clearly indicative of the invention to which the claims are directed. The following is suggested: "Nucleic Acid Encoding Plant Sugar Transport Proteins".

Correction is required.

Claim Objection

8. Claims 20-23 are objected to because of the following informalities:

Claims 20-23 are objected to because the claims have improper multiple dependent claims language. It is suggested that the claims are amended to recite "any one of claims 16 to 19".

Claim Rejections - 35 USC 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Art Unit: 1653

9. Claims 16-23 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Claims 16-23 are directed to an isolated nucleic acid fragment comprising a nucleotide sequence that encodes a sugar transport protein. However, the claimed invention lacks adequate written description because on page 23 of the instant specification it is stated that the plasmid was deposited under the terms of the Budapest Treaty at ATCC, but there is no indication as to whether the deposited material is publicly available or can be reproducibly isolated. Without publicly available deposit information one of skill in the art could not be assured of the ability to practice the invention as claimed. Applicant's referral to the deposited material in the instant specification is noted but is considered insufficient assurance that all of the conditions of 37 CFR 1.801-1.809 have been met. If deposits have not been made under the Budapest Treaty, then in order to certify that the deposits meet the criteria set forth in 37 CFR 1.801-1.809, applicant may provide assurance of compliance by an affidavit or declaration, or by a statement by an attorney of record over his or her signature and registration number, showing that:

- (A) During the pendency of this application, access to the invention will be afforded to the Commissioner upon request;
- (B) All restrictions upon availability to the public will be irrevocably removed upon granting of the patent;

Art Unit: 1653

(C) The deposits will be maintained in a public depository for a period of 30 years or 5 years after the last request or for the effective life of the patent, whichever is longer;

- (D) The deposits were viable at the time of deposit;
- (E) The deposits will be replaced if they should ever become non-viable.

This requirement is necessary when a deposit is made under the provisions of the Budapest Treaty as the Treaty leaves these specific matters to the discretion of each member State. Amendment of the specification to disclose the date of the deposit and the complete name and address of the depository is required.

For further information concerning deposit practice, applicants attention is directed to *In re Lundak* 773 F 2d 1216 227 USPQ CAFC and 37 CFR 1.801-1.809.

Therefore, for all these reasons the specification lacks adequate written description, and one of skill in the art cannot reasonably conclude that the applicant had possession of the claimed invention at the time the instant application was filed.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter, which the applicant regards as his invention.

10. Claim 19 is rejected under 35 U.S.C. 112, second paragraph, as failing to set forth the subject matter, which applicant (s) regard as their invention.

Art Unit: 1653

Claim 19 is indefinite for the recitation of "a nucleotide fragment corresponds to the nucleotide sequence set forth in SEQ ID NO:21" as it is unclear what corresponds to means in association with the claimed fragment, as "corresponds to" can be interpreted as equivalent or similar, thus the chemical structure is undefined.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Hope A. Robinson whose telephone number is 571-272-0957. The examiner can normally be reached on Monday-Friday from 9:00 a.m. to 6:30 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jon P. Weber, can be reached at (571) 272-0925.

The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Page 7

Hope Robinson, MS

Patent Examiner

Jon P. Weber, Ph.D. Primary Examiner